Biodistribution, Pharmacokinetics, and Dosimetry of 177Lu-, 90Y-, and 111In-Labeled Somatostatin Receptor Antagonist OPS201 in Comparison to the Agonist 177Lu-DOTATATE: The Mass Effect-Reference-Cited by-同舟云学术

Biodistribution, Pharmacokinetics, and Dosimetry of 177Lu-, 90Y-, and 111In-Labeled Somatostatin Receptor Antagonist OPS201 in Comparison to the Agonist 177Lu-DOTATATE: The Mass Effect

Published:2017-04-27 Issue:9 Volume:58 Page:1435-1441
ISSN:0161-5505
Container-title:Journal of Nuclear Medicine
language:en
Short-container-title:J Nucl Med

Author:

Nicolas Guillaume P.,Mansi Rosalba,McDougall Lisa,Kaufmann Jens,Bouterfa Hakim,Wild Damian,Fani Melpomeni

Publisher

Society of Nuclear Medicine

Subject

Radiology, Nuclear Medicine and imaging

Reference30 articles.

1. One Hundred Years After “Carcinoid”: Epidemiology of and Prognostic Factors for Neuroendocrine Tumors in 35,825 Cases in the United States

2. Gastroenteropancreatic neuroendocrine tumours

3. Recommendations for management of patients with neuroendocrine liver metastases

4. Peptide-receptor radionuclide therapy for endocrine tumors

5. Radiopeptide Imaging and Therapy in Europe

Cited by 108 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Comparison of the tolerability of 161Tb- and 177Lu-labeled somatostatin analogues in the preclinical setting;European Journal of Nuclear Medicine and Molecular Imaging;2024-07-24

2. Targeted Radionuclide Therapy in Glioblastoma;ACS Applied Materials & Interfaces;2024-07-23

3. Peptide Receptor Radionuclide Therapy of Neuroendocrine Tumors: Agonist, Antagonist and Alternatives;Seminars in Nuclear Medicine;2024-07

4. Design of a Fibroblast Activation Protein–Targeted Radiopharmaceutical Therapy with High Tumor–to–Healthy-Tissue Ratios;Journal of Nuclear Medicine;2024-06-13

5. CdTe XG‐Cam: A new high‐resolution x‐ray and gamma‐ray camera for studies of the pharmacokinetics of radiopharmaceuticals in small animals;Medical Physics;2024-05-19